Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
43 Leser
Artikel bewerten:
(0)

Diplomat Specialty Pharmacy Honored By Inc. Magazine as One Of The Nation's Fastest-Growing Companies for Fourth Consecutive Year

FLINT, Mich., Aug. 24, 2012 /PRNewswire/ --Diplomat Specialty Pharmacy announced today that, for the fourth consecutive year, they earned a position on Inc. magazine's exclusive, annual ranking of the fastest-growing private companies in America.

"We're proud to be recognized by Inc. again this year, earning a position of 1585 in the nation, but if you dig a little deeper into Inc.'s numbers, the details are even more remarkable," stated Phil Hagerman, CEO of Diplomat, referring to the facts that Diplomat:

  • Ranked #1 when combing revenue and growth rate of 2012 Inc. 5000 companies operating in the Health industry
  • Ranked #4 in total revenue of 2012 Inc. 5000 companies operating in the Health industry
  • Generated over$502 million in growth over 3 years

"To be honored this year is a particularly notable achievement," said Ed Schurenberg, Editor in Chief of Inc. magazine. "To rank among the 2012 Inc. 5000, [Diplomat] had to thrive through three of the toughest years this economy has seen in living memory. [Diplomat's] success in such times is eloquent testimony to their team's creativity, resilience and tenacity. Now, more than ever, we depend on Inc. 500/5000 companies to spur innovation, provide jobs, and drive the economy forward. Growth companies, not large corporations, are where the action is."

"Despite our unprecedented growth over the years, we've continued to stay dedicated to our patient focused model and achieved a 98% customer satisfaction response from our 2012 patient satisfaction survey. We could not achieve this without a tremendous staff committed to finding solutions for both patients and our healthcare partners," said Hagerman.

"As an Inc. 5000 honoree, Diplomat Specialty Pharmacy now shares a pedigree with Intuit, Zappos, Under Armor, Microsoft, Jamba Juice, Timberland, Clif Bar, Pandora, Patagonia and Oracle," said Schurenberg. "In addition to Diplomat Specialty Pharmacy the 2012 list added such powerhouses a Publix Supermarkets, CDW, Levi Strauss and a little social media company called Facebook."

About The Inc. 500/5000
The 2012 Inc. 500|5000 is ranked according to percentage revenue growth when comparing 2008 to 2011. To qualify, companies must have been founded and generating revenue by March 31, 2008. They had to be U.S.-based, privately held, for profit, and independent-not subsidiaries or divisions of other companies-as of December 31, 2011. (Since then, a number of companies on the list have gone public or been acquired.) The minimum revenue required for 2008 is $100,000; the minimum for 2011 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Companies on the Inc. 500 are featured in Inc.'s September issue. They represent the top tier of the Inc. 5000, which can be found at www.inc.com/500.

About Diplomat Specialty Pharmacy
Michigan-based Diplomat Specialty Pharmacy, founded in 1975, serves patients nationwide as the country's largest privately held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Diplomat's business model creates unique partnerships around both distribution and services with all industry stakeholders including physicians, patients, group purchasing organizations, hospital systems, retail chains and managed markets, always focused on improving adherence and the patient experience.

Learn more about Keeping Patients Healthier...Longer at www.diplomatpharmacy.com.

For more information contact:
Dan Roelofs, Communications Director, Diplomat Specialty Pharmacy
droelofs@diplomatpharmacy.com P: 616.808.3232

SOURCE Diplomat Specialty Pharmacy

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.